Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars. Collaboration aims to help patients worldwide gain access to a range of high-quality, affordable immunology and oncology biologics Partnership will be an important part of Sandoz and Biocon strategy to address the next wave of biosimilar opportunities globally; Collaboration will leverage combined strengths of development, manufacturing and commercialization of biosimilars; and Partnership provides foundation for expansion of portfolio. Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products, and will have a cost and profit share arrangement globally. Worldwide commercialization responsibilities will be divided and each company's strengths will be leveraged within specific geographies. Sandoz will lead commercialization in North America and the EU, while Biocon will lead commercialization in Rest of the World.